Ruti Aga and the Six-Year Arithmetic: The Prescription Was Fake, the Drug Was Not

10 September. That is the hinge of this entire case, and it is the least-read line in it. The decision the Athletics Integrity Unit (AIU) issued on Thursday runs six years, counted from 10 September — the day Ruti Aga (32, Ethiopia) was provisionally suspended. A sample taken after she won a half marathon in China in March returned an adverse finding. A knee injury was cited, a treatment record was produced, and the record turned out to be false.

On the surface this is another doping story. Open the structure of the sanction and it becomes something else: two years for presence of a substance, four years for tampering. The thing that ended a 2:18-class marathon career was not an injection. It was a forged prescription. The numbers were clean; the story underneath them was not.

Start with the correction most reports got wrong, because the error changes the legal foundation of the case. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and under the current List it is prohibited in-competition only — by injection, oral or rectal route. A therapeutic knee injection out of competition is entirely legal. The distinction matters because the question was never "steroid or no steroid". The question was route, dose and days-to-race. A road race's testing window opens at 23:59 the day before the race, so an injection given days earlier lands inside it.

I built the desk before I trusted the table. On the FIFA U-17 World Cup data desk in Delhi in 2026 I began putting sample size, source and a "what this metric cannot say" line under every column. At Russia 2026 that habit is what separated Spain's 74 per cent possession from its 2.1 xG. The same discipline applies here. This story contains no performance data — no time for the Chinese half marathon, no splits, no field strength. The one hard fact is that she won it, which tells us there was a testable, label-tier elite field. Anything beyond that is invention.

Now the part that is actually the news: the forgery chain. According to the AIU statement, the clinic named on the prescription did not exist. The "doctor" who signed it was a family member with no medical registration. Questioned, that person said an old prescription pad from a former workplace had been used — and the clinic explicitly disowned the claim. Three independent verifications, three failures. This is not a filing error. It is the signature of an athlete operating without a credentialed team physician.

Which is where my attention moves, as it usually does, to the payroll beneath the podium. Indian athletics has no professional contract, only sports-quota employment; East African road running runs on the opposite model, the appearance fee. For a 2:18–2:20 marathoner the most efficient economic strategy is two or three Majors a year with Asian label races in between, where the start money is good and the perceived risk is low. The Chinese half-marathon circuit sits exactly on that tier. The trouble is that the same tier is now the AIU's highest-yield testing ground. The fee economy and the testing economy are colliding in the same races, and an athlete with chronic knee pathology has the least room to manoeuvre inside that collision.

So read the six years as structure, not severity. Two years for a substance listed as specified — the standard period absent proven intent — plus four years for tampering, the Code's standard provision. First the ledger, then the legend — never the other way around. The arithmetic tells us the panel accepted presence as proven but rejected the no-significant-fault mitigation that would have shortened it, because an athlete with a genuine treatment defends it with genuine records, not a fabricated pad.

Backdating to 10 September is being read as relief. It is not. Provisional suspension time counts against the ban; the athlete gains nothing real. The sum is simple: six years at 32, a return at roughly 38. Given the depth of Ethiopian women's marathon running, where a sub-2:16 club is routine, a 38-year-old with a doping record is effectively unselectable. Six years on paper; a lifetime in practice.

One thing the reports leave out and should not: the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors do not annul themselves. Results before that March race stand unless earlier use is established, and the statement establishes nothing of the kind. Standard AIU practice voids the result and prize money from the competition where the sample was collected, so the March win and its fee are very likely gone even though the statement does not say so. Tokyo 2026 stays in the record book. I refuse both available comforts — the clean golden age and the wholesale damnation. Date the bans, name the mechanism, hold the era open.

Here is the angle that actually bothers me, and it is absent from the coverage. This six-year sanction will be cited as proof of AIU rigour. That is its weakest reading. Glucocorticoids have no established endurance benefit. The largest ban on the books therefore attaches to a substance whose performance upside is itself disputed. The deterrent message inverts: not "do not dope" but "if you are injured and under-resourced, do not manufacture paper". The athlete most likely to be caught is the one with the least credentialed medical support. Lengthening bans does not narrow that asymmetry; it widens it.

I have to put a brake on my own method here. After the Tokyo 2026 javelin final a producer wanted me to project 90 metres from Neeraj Chopra's 87.58m. I refused, because six throws do not establish a technique shift. The same discipline applies. This case is settled: the ban is a finding and gets written as one, not as a "debate". What is disputed is cause — ignorance, coaching negligence, or agent-level collusion. The statement names only the family member. Whether management was investigated is not disclosed. That is where both sides deserve airtime; the finding does not.

Also missing: the four-year tampering charge arises from an interview, not a document alone — from statements given under questioning. Language and translation conditions in AIU interviews with East African athletes are a recurring point of contention. I am not reopening the verdict on that basis; a finding is a finding. But the next time someone calls this a clean, textbook case, I will ask where the interview record is.

I don't chase outliers; I wait for them to repeat. And this one is repeating. Across East African road-running cases in recent years the pattern is consistent: the first charge is about a substance, the heavier second charge is about the explanation. The enforcement frontier has moved from detection to document verification. Over the next two years I want the AIU to publish how many of its cases it attributed to absent medical support, and how many it answered only with added years.

The limits of this piece, stated plainly: the year of the March race is not in the statement, the final year of the ban is not explicit, and no list of annulled results has been released. What is clear is this — a 32-year-old who won Tokyo in 2026 and finished second at three Majors is out of the next Olympic cycle entirely, and the thing that removed her was not a drug. It was a document.

When the next list appears, the first question is whether anyone credentialed signed that prescription, or whether it was a family member and an old pad. If it was the latter, the real question is not why Aga got six years. It is why she had no other route to treat a knee.